The vision for Mesoblast – to become the world leader in novel therapeutic approaches for patients with bone and joint diseases, including adult stem cell therapy for bone fractures and spinal disease, and for regeneration of damaged joint cartilage and intervertebral discs.

unique adult stem cell technology for orthopaedic applications for patients with bone and cartilage degeneration. Repair and regrowth of adult stem cells, Melbourne Australia
 

Mesoblast - adult stem cell technology, regeneration of adult stem cells, repair and regrowth of bone and cartilage Melbourne, Australia

Mesoblast - the regenerative medicine company

Mesoblast Limited (ACN 109 431 870) is an Australian biotechnology company committed to the development of novel treatments for orthopaedic conditions, including the commercialisation of unique adult stem cells to regenerate and repair bone and cartilage.

Mesoblast - The adult stem cell company. The vision for Mesoblast – to become the world leader in adult stem cell therapy for patients with bone and cartilage degeneration

Mesoblast Limited (ASX:MSB; USOTC:MBLTY), which listed on the Australian Stock Exchange in December 2004, has the worldwide exclusive rights for a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs).

The technology has achieved outstanding results in clinical and preclinical trials in the regeneration and repair of large bone fractures and cartilage.

The Company has also acquired a substantial equity holding in Angioblast Systems Inc, an American company developing the platform MPC technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology.

Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.

 

Last Share Price

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

23 August 2010 - EGM documents - Letter from the Chairman, Notice of Meeting, Independent Expert Report.

16 August - Mesoblast on track for phase 3 bone marrow transplant trial following positive meeting with FDA

21 July - Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products

12 July - Phase 3 meeting scheduled with FDA following positive results of bone marrow regeneration trial

28 May - Mesoblast featured at ASX Singapore conference highlighting emerging market leaders

19 May - United States FDA Clears Phase 2 Trial for Cervical Spinal Fusion

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine